FindTrial
Sign In

Median effective dose (ED50) of ropivacaine for obstetric cervical cerclage in Chinese women

Median effective dose (ED50) of ropivacaine for obstetric cervical cerclage in Chinese women

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100051418
Enrollment
Unknown
Registered
2021-09-23
Start date
2021-10-11
Completion date
Unknown
Last updated
2022-06-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obstetric cervical cerclage

Interventions

Ropivacaine group :Spinal anesthesia with ropivacaine

Sponsors

Shengjing Hospital of China Medical University
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1.Pregnant women in their second trimester; 2.Patients scheduled to undergo cervical cerclage under spinal anesthesia; 3.ASA physical status grade I-II; 4.Consent of patient or family member.

Exclusion criteria

Exclusion criteria: 1.Contraindications of spinal anesthesia (coagulopathy, spinal deformity, infection at puncture site, etc.); 2.Allergy to ropivacaine.

Design outcomes

Primary

MeasureTime frame
Anesthesia and operation time;Changes in blood pressure and heart rate;From the time the drug is administered to the time the anesthesia takes effect;Time from dosing to reaching the T10 plane;Time from administration to reaching the highest level of anesthesia;Sensory recovery time;Exercise recovery time;—

Secondary

MeasureTime frame
Dose of ropivacaine;Blood pressure;Heart rate;The maximum block level;Complications;—

Countries

China

Contacts

Public ContactTao Bingdong

Shengjing Hospital of China Medical University

taobd@icloud.com+86 18940255594

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 10, 2026